Boonen Lieke H H M, van der Geest Stéphanie A, Schut Frederik T, Varkevisser Marco
Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands.
Adv Health Econ Health Serv Res. 2010;22:53-76. doi: 10.1108/s0731-2199(2010)0000022006.
To analyse the development of pharmaceutical policy in the Dutch market for outpatient prescription drugs since the early 1990s.
A literature review and document analysis is performed to examine the effects of pharmaceutical policy on the performance of the Dutch market for outpatient prescription drugs since the early 1990s.
Government efforts to control prices of pharmaceuticals were effective in constraining prices of in-patent drugs, but had an opposite effect on the prices of generic drugs. The gradual transition towards managed competition--that particularly gained momentum after the introduction of the new universal health insurance scheme in 2006--appears to be more effective in constraining prices of generic drugs than earlier government efforts to control these prices.
Comparative analysis of the impact of price regulation and managed competition on generic drug prices in the Netherlands.
Implications of the changing role of health insurers are discussed for the future market for prescription drugs and role of pharmacies in the Netherlands.
分析自20世纪90年代初以来荷兰门诊处方药市场的药品政策发展情况。
进行文献综述和文件分析，以研究自20世纪90年代初以来药品政策对荷兰门诊处方药市场表现的影响。
政府控制药品价格的努力在抑制专利药价格方面有效，但对非专利药价格却产生了相反的影响。向管理式竞争的逐步转变——尤其是在2006年引入新的全民健康保险计划后势头更劲——在抑制非专利药价格方面似乎比政府早期控制这些价格的努力更有效。
对荷兰价格监管和管理式竞争对非专利药价格的影响进行比较分析。
讨论了健康保险公司角色变化对荷兰未来处方药市场及药店角色的影响。
